Adhera Therapeutics, Inc. (OTCMKTS:ATRX) Short Interest Down 95.0% in March

Adhera Therapeutics, Inc. (OTCMKTS:ATRX) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 100 shares, a decline of 95.0% from the February 29th total of 2,000 shares. Based on an average daily trading volume, of 220,800 shares, the short-interest ratio is presently 0.0 days.

Adhera Therapeutics Price Performance

ATRX opened at $0.01 on Thursday. The company has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.02. Adhera Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.60.

Adhera Therapeutics Company Profile

Adhera Therapeutics, Inc, a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc and changed its name to Adhera Therapeutics, Inc in October 2018.